Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aclaris Therapeutics, Inc.ACRS · Entity 5041 | Director · CEO | February 02, 2026 | February 06, 2026 |
| Aldeyra Therapeutics, Inc.ALDX · Entity 6839 | Director | June 09, 2026 | June 11, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aclaris Therapeutics, Inc.
Report date February 02, 2026 · Filed February 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 274,800 |
Reported balance
After 2026-02-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-02 · Grant · Acquired 274,800 · Balance 274,800 F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F2: The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 2, 2026, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.61 · Expires 2036-02-01 | Direct | 961,700 |
Reported balance
After 2026-02-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-02-02 · Grant · Acquired 961,700 · Balance 961,700 F3: Exercisable with respect to 25% of the shares subject to the option vesting in four equal installments on the first, second, third and fourth anniversaries of February 2, 2026, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
F2: The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 2, 2026, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date.
F3: Exercisable with respect to 25% of the shares subject to the option vesting in four equal installments on the first, second, third and fourth anniversaries of February 2, 2026, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date.
Aldeyra Therapeutics, Inc.
Report date June 09, 2026 · Filed June 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.72 · Expires 2036-06-08 | Direct | 70,000 |
Reported balance
After 2026-06-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-09 · Grant · Acquired 70,000 · Balance 70,000 F1: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.72 · Expires 2036-06-08 | Direct | 3,318 |
Reported balance
After 2026-06-09 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-09 · Grant · Acquired 3,318 · Balance 3,318 F2: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Compensation Committee of the Board of Directors of the Issuer through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date.
F2: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Compensation Committee of the Board of Directors of the Issuer through the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 01, 2024 Filed Aug 5, 2024 20:15 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 9,467 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-020740 · form4-08052024_040814.xml · derivative · entry 3 Walker Neal · CIK 0001604457 · Director · INTERIM PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,200 Underlying: Common Stock · 9,467 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F3 · derivative.exercise_date: The shares vest in equal monthly installments over 15 months beginning February 1, 2024, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as the Interim CEO to the Company as of each such vesting date, provided that in the event he ceases to be Interim CEO but continues to provide Continuous Service in any capacity, such awards will continue to vest in the event that the Issuer's Board of Directors determines in its sole discretion that he achieved the Performance Goals (as defined in his letter agreement of employment as Interim CEO) prior to the cessation of his employment as Interim CEO. F3 · derivative.expiration_date: The shares vest in equal monthly installments over 15 months beginning February 1, 2024, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as the Interim CEO to the Company as of each such vesting date, provided that in the event he ceases to be Interim CEO but continues to provide Continuous Service in any capacity, such awards will continue to vest in the event that the Issuer's Board of Directors determines in its sole discretion that he achieved the Performance Goals (as defined in his letter agreement of employment as Interim CEO) prior to the cessation of his employment as Interim CEO. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 20:15 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Tax withholdingCommon Stock | 2,722 | $1.32 | $3,593.04 |
DisclosureSEC source: 0001415889-24-020740 · form4-08052024_040814.xml · nonDerivative · entry 2 Walker Neal · CIK 0001604457 · Director · INTERIM PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,312,605 F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 20:15 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 9,467 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-020740 · form4-08052024_040814.xml · nonDerivative · entry 1 Walker Neal · CIK 0001604457 · Director · INTERIM PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,315,327 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document |
| July 01, 2024 Filed Jul 3, 2024 20:15 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 9,467 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-019172 · form4-07032024_040707.xml · derivative · entry 3 Walker Neal · CIK 0001604457 · Director · INTERIM PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 94,667 Underlying: Common Stock · 9,467 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F3 · derivative.exercise_date: The shares vest in equal monthly installments over 15 months beginning February 1, 2024, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as the Interim CEO to the Company as of each such vesting date, provided that in the event he ceases to be Interim CEO but continues to provide Continuous Service in any capacity, such awards will continue to vest in the event that the Issuer's Board of Directors determines in its sole discretion that he achieved the Performance Goals (as defined in his letter agreement of employment as Interim CEO) prior to the cessation of his employment as Interim CEO. F3 · derivative.expiration_date: The shares vest in equal monthly installments over 15 months beginning February 1, 2024, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as the Interim CEO to the Company as of each such vesting date, provided that in the event he ceases to be Interim CEO but continues to provide Continuous Service in any capacity, such awards will continue to vest in the event that the Issuer's Board of Directors determines in its sole discretion that he achieved the Performance Goals (as defined in his letter agreement of employment as Interim CEO) prior to the cessation of his employment as Interim CEO. Read SEC document |
| July 01, 2024 Filed Jul 3, 2024 20:15 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Tax withholdingCommon Stock | 2,722 | $1.15 | $3,130.30 |
DisclosureSEC source: 0001415889-24-019172 · form4-07032024_040707.xml · nonDerivative · entry 2 Walker Neal · CIK 0001604457 · Director · INTERIM PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,305,860 F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4. Read SEC document |
| July 01, 2024 Filed Jul 3, 2024 20:15 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 9,467 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-019172 · form4-07032024_040707.xml · nonDerivative · entry 1 Walker Neal · CIK 0001604457 · Director · INTERIM PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,308,582 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document |
| June 04, 2024 Filed Jun 6, 2024 20:12 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantStock Option (Right to Buy) · Derivative | 1,736 | $0.00 Strike: $4.09 | $0.00 |
DisclosureSEC source: 0000950170-24-069888 · ownership.xml · derivative · entry 2 Walker Neal · CIK 0001604457 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,736 Underlying: Common Stock · 1,736 shares Expires 2034-06-03 F2 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Compensation Committee of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document |
| June 04, 2024 Filed Jun 6, 2024 20:12 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantStock Option (Right to Buy) · Derivative | 40,282 | $0.00 Strike: $4.09 | $0.00 |
DisclosureSEC source: 0000950170-24-069888 · ownership.xml · derivative · entry 1 Walker Neal · CIK 0001604457 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,282 Underlying: Common Stock · 40,282 shares Expires 2034-06-03 F1 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document |
| June 01, 2024 Filed Jun 4, 2024 20:30 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 9,466 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-015371 · form4-06042024_040622.xml · derivative · entry 3 Walker Neal · CIK 0001604457 · Director · INTERIM PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 104,134 Underlying: Common Stock · 9,466 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F3 · derivative.exercise_date: The shares vest in equal monthly installments over 15 months beginning February 1, 2024, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as the Interim CEO to the Company as of each such vesting date, provided that in the event he ceases to be Interim CEO but continues to provide Continuous Service in any capacity, such awards will continue to vest in the event that the Issuer's Board of Directors determines in its sole discretion that he achieved the Performance Goals (as defined in his letter agreement of employment as Interim CEO) prior to the cessation of his employment as Interim CEO. F3 · derivative.expiration_date: The shares vest in equal monthly installments over 15 months beginning February 1, 2024, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as the Interim CEO to the Company as of each such vesting date, provided that in the event he ceases to be Interim CEO but continues to provide Continuous Service in any capacity, such awards will continue to vest in the event that the Issuer's Board of Directors determines in its sole discretion that he achieved the Performance Goals (as defined in his letter agreement of employment as Interim CEO) prior to the cessation of his employment as Interim CEO. Read SEC document |
| June 01, 2024 Filed Jun 4, 2024 20:30 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Tax withholdingCommon Stock | 2,722 | $1.03 | $2,803.66 |
DisclosureSEC source: 0001415889-24-015371 · form4-06042024_040622.xml · nonDerivative · entry 2 Walker Neal · CIK 0001604457 · Director · INTERIM PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,299,115 F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4. Read SEC document |
| June 01, 2024 Filed Jun 4, 2024 20:30 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 9,466 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-015371 · form4-06042024_040622.xml · nonDerivative · entry 1 Walker Neal · CIK 0001604457 · Director · INTERIM PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,301,837 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document |
| May 01, 2024 Filed May 3, 2024 20:20 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 9,467 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-012167 · form4-05032024_040502.xml · derivative · entry 3 Walker Neal · CIK 0001604457 · Director · INTERIM PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 113,600 Underlying: Common Stock · 9,467 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F3 · derivative.exercise_date: The shares vest in equal monthly installments over 15 months beginning February 1, 2024, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as the Interim CEO to the Company as of each such vesting date, provided that in the event he ceases to be Interim CEO but continues to provide Continuous Service in any capacity, such awards will continue to vest in the event that the Issuer's Board of Directors determines in its sole discretion that he achieved the Performance Goals (as defined in his letter agreement of employment as Interim CEO) prior to the cessation of his employment as Interim CEO. F3 · derivative.expiration_date: The shares vest in equal monthly installments over 15 months beginning February 1, 2024, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as the Interim CEO to the Company as of each such vesting date, provided that in the event he ceases to be Interim CEO but continues to provide Continuous Service in any capacity, such awards will continue to vest in the event that the Issuer's Board of Directors determines in its sole discretion that he achieved the Performance Goals (as defined in his letter agreement of employment as Interim CEO) prior to the cessation of his employment as Interim CEO. Read SEC document |
| May 01, 2024 Filed May 3, 2024 20:20 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Tax withholdingCommon Stock | 2,784 | $1.26 | $3,507.84 |
DisclosureSEC source: 0001415889-24-012167 · form4-05032024_040502.xml · nonDerivative · entry 2 Walker Neal · CIK 0001604457 · Director · INTERIM PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,292,371 F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4. Read SEC document |
| May 01, 2024 Filed May 3, 2024 20:20 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 9,467 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-012167 · form4-05032024_040502.xml · nonDerivative · entry 1 Walker Neal · CIK 0001604457 · Director · INTERIM PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,295,155 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 21:00 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 9,467 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-010060 · form4-04032024_090431.xml · derivative · entry 3 Walker Neal · CIK 0001604457 · Director · INTERIM PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 123,067 Underlying: Common Stock · 9,467 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F3 · derivative.exercise_date: The shares vest in equal monthly installments over 15 months beginning February 1, 2024, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as the Interim CEO to the Company as of each such vesting date, provided that in the event he ceases to be Interim CEO but continues to provide Continuous Service in any capacity, such awards will continue to vest in the event that the Issuer's Board of Directors determines in its sole discretion that he achieved the Performance Goals (as defined in his letter agreement of employment as Interim CEO) prior to the cessation of his employment as Interim CEO. F3 · derivative.expiration_date: The shares vest in equal monthly installments over 15 months beginning February 1, 2024, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as the Interim CEO to the Company as of each such vesting date, provided that in the event he ceases to be Interim CEO but continues to provide Continuous Service in any capacity, such awards will continue to vest in the event that the Issuer's Board of Directors determines in its sole discretion that he achieved the Performance Goals (as defined in his letter agreement of employment as Interim CEO) prior to the cessation of his employment as Interim CEO. Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 21:00 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Tax withholdingCommon Stock | 3,224 | $1.26 | $4,062.24 |
DisclosureSEC source: 0001415889-24-010060 · form4-04032024_090431.xml · nonDerivative · entry 2 Walker Neal · CIK 0001604457 · Director · INTERIM PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,285,688 F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4. Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 21:00 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 9,467 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-010060 · form4-04032024_090431.xml · nonDerivative · entry 1 Walker Neal · CIK 0001604457 · Director · INTERIM PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,288,912 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 22:08 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 9,466 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-004407 · doc4.xml · derivative · entry 3 Walker Neal · CIK 0001604457 · Director · Interim President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 132,534 Underlying: Common Stock · 9,466 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F3 · derivative.exercise_date: The shares vest in equal monthly installments over 15 months beginning February 1, 2024, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as the Interim CEO to the Company as of each such vesting date, provided that in the event he ceases to be Interim CEO but continues to provide Continuous Service in any capacity, such awards will continue to vest in the event that the Issuer's Board of Directors determines in its sole discretion that he achieved the Performance Goals (as defined in his letter agreement of employment as Interim CEO) prior to the cessation of his employment as Interim CEO. F3 · derivative.expiration_date: The shares vest in equal monthly installments over 15 months beginning February 1, 2024, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as the Interim CEO to the Company as of each such vesting date, provided that in the event he ceases to be Interim CEO but continues to provide Continuous Service in any capacity, such awards will continue to vest in the event that the Issuer's Board of Directors determines in its sole discretion that he achieved the Performance Goals (as defined in his letter agreement of employment as Interim CEO) prior to the cessation of his employment as Interim CEO. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 22:08 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Tax withholdingCommon Stock | 3,223 | $1.24 | $3,996.52 |
DisclosureSEC source: 0001209191-24-004407 · doc4.xml · nonDerivative · entry 2 Walker Neal · CIK 0001604457 · Director · Interim President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,279,445 F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 22:08 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 9,466 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-24-004407 · doc4.xml · nonDerivative · entry 1 Walker Neal · CIK 0001604457 · Director · Interim President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,282,668 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document |
| February 01, 2024 Filed Feb 6, 2024 00:36 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GrantRestricted Stock Units · Derivative | 142,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-002842 · doc4.xml · derivative · entry 2 Walker Neal · CIK 0001604457 · Director · Interim CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 142,000 Underlying: Common Stock · 142,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F1 · derivative.exercise_date: The shares vest in equal monthly installments over 15 months beginning February 1, 2024, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as the Interim CEO to the Company as of each such vesting date, provided that in the event he ceases to be Interim CEO but continues to provide Continuous Service in any capacity, such awards will continue to vest in the event that the Issuer's Board of Directors determines in its sole discretion that he achieved the Performance Goals (as defined in his letter agreement of employment as Interim CEO) prior to the cessation of his employment as Interim CEO. F1 · derivative.expiration_date: The shares vest in equal monthly installments over 15 months beginning February 1, 2024, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as the Interim CEO to the Company as of each such vesting date, provided that in the event he ceases to be Interim CEO but continues to provide Continuous Service in any capacity, such awards will continue to vest in the event that the Issuer's Board of Directors determines in its sole discretion that he achieved the Performance Goals (as defined in his letter agreement of employment as Interim CEO) prior to the cessation of his employment as Interim CEO. Read SEC document |
| February 01, 2024 Filed Feb 6, 2024 00:36 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GrantStock Option (Right to Buy) · Derivative | 497,000 | $0.00 Strike: $1.20 | $0.00 |
DisclosureSEC source: 0001209191-24-002842 · doc4.xml · derivative · entry 1 Walker Neal · CIK 0001604457 · Director · Interim CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 497,000 Underlying: Common Stock · 497,000 shares Expires 2034-01-31 F1 · derivative.exercise_date: The shares vest in equal monthly installments over 15 months beginning February 1, 2024, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as the Interim CEO to the Company as of each such vesting date, provided that in the event he ceases to be Interim CEO but continues to provide Continuous Service in any capacity, such awards will continue to vest in the event that the Issuer's Board of Directors determines in its sole discretion that he achieved the Performance Goals (as defined in his letter agreement of employment as Interim CEO) prior to the cessation of his employment as Interim CEO. Read SEC document |
| August 22, 2023 Filed Aug 24, 2023 20:13 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | Exercise / conversionStock Option (Right to Buy) · Derivative | 9,604 | $0.00 Strike: $0.55 | $0.00 |
DisclosureSEC source: 0000950170-23-044379 · ownership.xml · derivative · entry 2 Walker Neal · CIK 0001604457 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,604 shares Expires 2023-09-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option is fully vested. Read SEC document |
| August 22, 2023 Filed Aug 24, 2023 20:13 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | Exercise / conversionCommon Stock | 9,604 | $0.55 | $5,301.41 |
DisclosureSEC source: 0000950170-23-044379 · ownership.xml · nonDerivative · entry 1 Walker Neal · CIK 0001604457 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,854 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 30, 2023 Filed Jul 5, 2023 21:30 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantStock Option (Right to Buy) · Derivative | 915 | $0.00 Strike: $8.39 | $0.00 |
DisclosureSEC source: 0000950170-23-031775 · ownership.xml · derivative · entry 2 Walker Neal · CIK 0001604457 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 915 Underlying: Common Stock · 915 shares Expires 2033-06-29 F2 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Compensation Committee of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document |
| June 30, 2023 Filed Jul 5, 2023 21:30 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantStock Option (Right to Buy) · Derivative | 21,222 | $0.00 Strike: $8.39 | $0.00 |
DisclosureSEC source: 0000950170-23-031775 · ownership.xml · derivative · entry 1 Walker Neal · CIK 0001604457 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,222 Underlying: Common Stock · 21,222 shares Expires 2033-06-29 F1 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document |
| March 03, 2023 Filed Mar 4, 2023 01:37 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | SaleCommon Stock | 30,240 | $12.63 | $382,070.30 |
DisclosureSEC source: 0001209191-23-016074 · doc4.xml · nonDerivative · entry 6 Walker Neal · CIK 0001604457 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,273,202 F4 · kind: Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for restricted stock units that vested on March 1, 2023 and March 2, 2023 pursuant to preexisting sell-to-cover elections. F5 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $12.39 to $12.93, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 02, 2023 Filed Mar 4, 2023 01:37 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 18,254 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-016074 · doc4.xml · derivative · entry 10 Walker Neal · CIK 0001604457 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,254 Underlying: Common Stock · 18,254 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F9 · derivative.exercise_date: The shares underlying these restricted stock units were originally scheduled to vest in four equal annual installments beginning on March 2, 2021, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. Pursuant to the Letter Agreement dated November 22, 2022 the shares underlying these restricted stock units will cease vesting on December 31, 2023. F9 · derivative.expiration_date: The shares underlying these restricted stock units were originally scheduled to vest in four equal annual installments beginning on March 2, 2021, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. Pursuant to the Letter Agreement dated November 22, 2022 the shares underlying these restricted stock units will cease vesting on December 31, 2023. Read SEC document |
| March 02, 2023 Filed Mar 4, 2023 01:37 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 18,254 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-016074 · doc4.xml · nonDerivative · entry 5 Walker Neal · CIK 0001604457 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,303,442 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document |
| March 02, 2023 Filed Mar 4, 2023 01:37 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | SaleCommon Stock | 29,000 | $12.37 | $358,587.90 |
DisclosureSEC source: 0001209191-23-016074 · doc4.xml · nonDerivative · entry 4 Walker Neal · CIK 0001604457 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,285,188 F2 · kind: Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for restricted stock units that vested on March 1, 2023 pursuant to preexisting sell-to-cover elections. F3 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $11.88 to $12.69, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 01, 2023 Filed Mar 4, 2023 01:37 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 24,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-016074 · doc4.xml · derivative · entry 9 Walker Neal · CIK 0001604457 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,000 Underlying: Common Stock · 24,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F8 · derivative.exercise_date: The shares underlying these restricted stock units were originally scheduled to vest in four equal annual installments beginning on March 1, 2023, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. Pursuant to the Letter Agreement dated November 22, 2022 the shares underlying these restricted stock units will cease vesting on December 31, 2023. F8 · derivative.expiration_date: The shares underlying these restricted stock units were originally scheduled to vest in four equal annual installments beginning on March 1, 2023, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. Pursuant to the Letter Agreement dated November 22, 2022 the shares underlying these restricted stock units will cease vesting on December 31, 2023. Read SEC document |
| March 01, 2023 Filed Mar 4, 2023 01:37 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 18,275 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-016074 · doc4.xml · derivative · entry 8 Walker Neal · CIK 0001604457 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,550 Underlying: Common Stock · 18,275 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F7 · derivative.exercise_date: The shares underlying these restricted stock units were originally scheduled to vest in four equal annual installments beginning on March 1, 2022, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. Pursuant to the Letter Agreement dated November 22, 2022 the shares underlying these restricted stock units will cease vesting on December 31, 2023. F7 · derivative.expiration_date: The shares underlying these restricted stock units were originally scheduled to vest in four equal annual installments beginning on March 1, 2022, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. Pursuant to the Letter Agreement dated November 22, 2022 the shares underlying these restricted stock units will cease vesting on December 31, 2023. Read SEC document |
| March 01, 2023 Filed Mar 4, 2023 01:37 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 96,150 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-016074 · doc4.xml · derivative · entry 7 Walker Neal · CIK 0001604457 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 96,150 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F6 · derivative.exercise_date: The shares underlying these restricted stock units were originally scheduled to vest in four equal annual installments beginning on March 1, 2020, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. Pursuant to the Letter Agreement dated November 22, 2022 the shares underlying these restricted stock units will cease vesting on December 31, 2023. F6 · derivative.expiration_date: The shares underlying these restricted stock units were originally scheduled to vest in four equal annual installments beginning on March 1, 2020, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. Pursuant to the Letter Agreement dated November 22, 2022 the shares underlying these restricted stock units will cease vesting on December 31, 2023. Read SEC document |
| March 01, 2023 Filed Mar 4, 2023 01:37 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 24,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-016074 · doc4.xml · nonDerivative · entry 3 Walker Neal · CIK 0001604457 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,314,188 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document |
| March 01, 2023 Filed Mar 4, 2023 01:37 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 18,275 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-016074 · doc4.xml · nonDerivative · entry 2 Walker Neal · CIK 0001604457 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,290,188 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document |
| March 01, 2023 Filed Mar 4, 2023 01:37 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 96,150 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-016074 · doc4.xml · nonDerivative · entry 1 Walker Neal · CIK 0001604457 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,271,913 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document |
| February 02, 2023 Filed Feb 3, 2023 22:09 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | SaleCommon Stock | 200 | $17.54 | $3,507.00 |
DisclosureSEC source: 0001209191-23-007032 · doc4.xml · nonDerivative · entry 5 Walker Neal · CIK 0001604457 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,175,763 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 2, 2022. F6 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $17.51 to $17.56, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote Read SEC document |
| February 02, 2023 Filed Feb 3, 2023 22:09 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | SaleCommon Stock | 3,121 | $16.88 | $52,690.91 |
DisclosureSEC source: 0001209191-23-007032 · doc4.xml · nonDerivative · entry 4 Walker Neal · CIK 0001604457 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,175,963 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 2, 2022. F5 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $16.51 to $17.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote Read SEC document |
| February 02, 2023 Filed Feb 3, 2023 22:09 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | SaleCommon Stock | 600 | $15.55 | $9,331.98 |
DisclosureSEC source: 0001209191-23-007032 · doc4.xml · nonDerivative · entry 3 Walker Neal · CIK 0001604457 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,179,084 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 2, 2022. F4 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $15.27 to $15.84, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote Read SEC document |
| February 02, 2023 Filed Feb 3, 2023 22:09 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | SaleCommon Stock | 1,079 | $14.57 | $15,717.90 |
DisclosureSEC source: 0001209191-23-007032 · doc4.xml · nonDerivative · entry 2 Walker Neal · CIK 0001604457 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,179,684 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 2, 2022. F3 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $14.25 to $15.22, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 22:09 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | SaleCommon Stock | 25,000 | $16.75 | $418,675.00 |
DisclosureSEC source: 0001209191-23-007032 · doc4.xml · nonDerivative · entry 1 Walker Neal · CIK 0001604457 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,180,763 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 2, 2022. F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $16.28 to $17.14, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 04, 2023 Filed Jan 4, 2023 23:20 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | SaleCommon Stock | 15,000 | $14.89 | $223,342.50 |
DisclosureSEC source: 0001209191-23-001329 · doc4.xml · nonDerivative · entry 3 Walker Neal · CIK 0001604457 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,205,763 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 2, 2022. F4 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $14.65 to $15.29, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 03, 2023 Filed Jan 4, 2023 23:20 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | SaleCommon Stock | 1,618 | $16.16 | $26,145.91 |
DisclosureSEC source: 0001209191-23-001329 · doc4.xml · nonDerivative · entry 2 Walker Neal · CIK 0001604457 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,220,763 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 2, 2022. F3 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $15.92 to $16.44, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 03, 2023 Filed Jan 4, 2023 23:20 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | SaleCommon Stock | 23,382 | $15.19 | $355,067.36 |
DisclosureSEC source: 0001209191-23-001329 · doc4.xml · nonDerivative · entry 1 Walker Neal · CIK 0001604457 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,222,381 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 2, 2022. F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $14.89 to $15.88, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 07, 2022 Filed Jun 9, 2022 21:04 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantStock Option (Right to Buy) · Derivative | 2,319 | $0.00 Strike: $3.60 | $0.00 |
DisclosureSEC source: 0000899243-22-021626 · doc4.xml · derivative · entry 2 Walker Neal · CIK 0001604457 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,319 Underlying: Common Stock · 2,319 shares Expires 2032-06-06 F2 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Compensation Committee of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document |
| June 07, 2022 Filed Jun 9, 2022 21:04 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantStock Option (Right to Buy) · Derivative | 53,812 | $0.00 Strike: $3.60 | $0.00 |
DisclosureSEC source: 0000899243-22-021626 · doc4.xml · derivative · entry 1 Walker Neal · CIK 0001604457 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,812 Underlying: Common Stock · 53,812 shares Expires 2032-06-06 F1 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document |
| April 25, 2022 Filed Apr 25, 2022 21:13 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | SaleCommon Stock | 20,000 | $15.18 | $303,656.00 |
DisclosureSEC source: 0001209191-22-025537 · doc4.xml · nonDerivative · entry 3 Walker Neal · CIK 0001604457 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,245,763 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 22, 2022. F4 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $15.00 to $15.33, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 22, 2022 Filed Apr 25, 2022 21:13 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | SaleCommon Stock | 25,000 | $15.04 | $376,097.50 |
DisclosureSEC source: 0001209191-22-025537 · doc4.xml · nonDerivative · entry 2 Walker Neal · CIK 0001604457 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,265,763 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 22, 2022. F3 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $15.00 to $15.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 21, 2022 Filed Apr 25, 2022 21:13 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | SaleCommon Stock | 25,000 | $15.24 | $380,947.50 |
DisclosureSEC source: 0001209191-22-025537 · doc4.xml · nonDerivative · entry 1 Walker Neal · CIK 0001604457 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,290,763 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 22, 2022. F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $15.00 to $15.77, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 11, 2022 Filed Mar 14, 2022 20:58 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | SaleCommon Stock | 56,303 | $15.91 | $896,045.35 |
DisclosureSEC source: 0001209191-22-018516 · doc4.xml · nonDerivative · entry 1 Walker Neal · CIK 0001604457 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,315,763 F1 · kind: Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for restricted stock units that vested on March 1, 2022 and March 2, 2022 pursuant to preexisting sell-to-cover elections. F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $15.72 to $16.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.